Q1: Quarterly Industry Update

AS OF March 31, 2025



Medical Recordkeeping Industry Summary

COGENT VALUATION identified Medical Recordkeeping publicly traded companies, IPOs, and recent M&A transactions within the Medical Recordkeeping industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since December 31, 2023, the median 52-week share price return of the Medical Recordkeeping industry was 19.2%, and the median YTD was 19.2%. Between December 31, 2023 and March 31, 2025, the median EV/Revenue multiple decreased from 1.8 to .7 and the median EV/EBITDA multiple increased from 10.2 to 16.5 The median price-to-earnings multiple increased from 15.4 to 21.3x and the median EV/Gross CF multiple decreased from 32.3 to 29.1 over the same period. The median MVIC/Earnings multiple decreased from 4.2 to 4.1. The median Price/Revenue multiple increased from 14 to 15.6 over the same period.

Public Company
Key Statistics

Median 52-Week Return

19.2%

19.2%

Median YTD Return

Median MVIC/ Earnings Multiple

4.1x

Median EV/Revenue Multiple

4.1x

16.5x

Multiple

Median EV/EBITDA

/ Itiple

Multiple 15.6x

Median Price/Revenue

Median Price/Earnings Multiple

21.3x

17.1x

Profit Multiple

Median EV/Gross

Public Company Median Multiples by Quarter

	3/31/25	12/31/24	9/30/24	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23
Median EV/Revenue Multiple	4.1x	3.2x	3.4x	1.7x	3.1x	3.2x	2.9x	3.0x
Median EV/EBITDA Multiple	16.5x	18.0x	17.6x	13.4x	14.6x	14.6x	19.4x	10.7x
Median Price/Earnings Multiple	21.3x	30.1x	20.3x	21.2x	20.8x	19.7x	17.9x	17.7x
Median EV/Gross Profit Multiple	17.1x	21.3x	21.3x	23.6x	24.5x	13.3x	20.4x	25.9x
Median MVIC/Earnings Multiple	4.1x	11.6x	12.7x	13.7x	15.4x	16.5x	12.2x	13.2x
Median Price/ Revenue Multiple	15.6x	3.2x	3.4x	2.7x	10.6x	2.5x	3.2x	3.2x
	Highest I	Multiplo	Median M	Aultinlo -	Lowest Mul	tinlo		

Highest Multiple Median Multiple

Comparable Public Company Market Price Returns as of March 31, 2025

Company Name	Q1 2025	One Year ¹	Two Year¹	Three Year¹	2024	2023	2022
Allscripts Healthcare Solutions, Inc.	-15.1%	1.1%	-2.7%	42.5%	-33.6%	20.4%	-17.4%
athenahealth, Inc.	7.5%	6.2%	-9.1%	26.5%	-34.7%	10.5%	8.3%
Cerner Corporation	-13.9%	-7.5%	5.8%	42.3%	-21.3%	-6.9%	16.0%
Computer Programs and Systems	22.4%	19.2%	-22.3%	27.3%	-52.6%	-18.1%	-1.7%
Nuance Communications, Inc.	-3.7%	3.2%	-9.3%	9.7%	-25.1%	39.4%	-6.1%
Quality Systems, Inc.	0.5%	5.1%	-8.2%	3.3%	-19.2%	3.4%	-26.0%
Streamline Health Solutions, Inc.	8.9%	-19.7%	9.5%	35.2%	-11.3%	-67.4%	-38.0%
Median of Industry Public Companies	22.4%	19.2%	-8.2%	27.3%	-25.1%	3.4%	-6.1%



[1] Calculated as the average annual return.

Industry Initial Public Offerings—Medical Recordkeeping (dollars in millions, except share prices)

Effective Date	Company Name	Offer Price	Shares Offered	Amount Raised	Total Assets¹	Debt¹	LTM Revenue¹	LTM EBITDA¹	LTM Net Income	LTM Cash Flows¹
3/15/25	Press Ganey Holdings, Inc.	\$25.00	8.9	\$222.5	\$910.1	\$416.2	\$291.1	\$92.8	\$18.3	\$112.9
12/6/24	Premier, Inc.	\$27.00	28.2	\$760.1	\$598.9	\$34.6	\$869.3	\$407.1	\$7.4	\$434.7
12/27/22	Vocera Communications, Inc.	\$16.00	5.9	\$93.6	\$49.8	\$8.3	\$79.5	\$1.2	(\$2.5)	\$2.2
12/1/22	Greenway Medical Technologies, Inc.	\$10.00	6.7	\$66.7	\$83.2	\$0.0	\$105.8	\$6.3	\$34.4	\$7.5
2/1/22	Epocrates, Inc.	\$16.00	5.4	\$85.8	\$121.3	\$0.0	N/A	N/A	N/A	N/A
12/21/21	DynaVox Inc.	\$15.00	9.4	\$140.6	\$128.4	\$79.2	\$111.7	\$28.1	\$13.5	\$30.7
5/20/15	Median of all IPOs	nm	nm	\$117.1	\$125.3	\$21.5	\$111.7	\$28.1	\$13.5	\$30.7

[1] As of the effective date of the IPO

Size of Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transaction Date	Target	Acquirer	Transaction Size	% Bought	LTM Revenues¹	EV/ Revenues
3/5/25	G4S Secure Data Solutions	Metrofile Holdings Limited	\$32.7	100%	\$10.2	2.8x
3/6/25	Healthsciences International	New Silkroutes Group	\$435.0	100%	\$37.3	5.1x
2/9/24	QHR Corporation	Shoppers Drug Mart Inc.	\$106.6	100%	\$93.0	5.4x
12/6/23	Verisk Health, Inc.	Veritas Capital	\$17.3	100%	\$43.2	1.4x
1/24/23	Netsmart Technologies Inc.	GI Partners, LLC	\$160.0	100%	\$6.2	5.3x
9/30/23	Capita Medical Reporting	N/A	\$176.8	100%	\$91.2	1.4x
8/3/22	RSA Medical, LLC	Xerox Corporation	\$500.0	100%	\$2.0	10.0x
11/3/21	Ascribe	Imprivata, Inc.	\$600.0	100%	\$6.1	7.3x
10/31/21	Epocrates	Market Resource Partners	\$20.0	100%	\$18.1	7.4x
2/28/21	Strand Technology	Corporate Executive Board	\$45.0	100%	\$9.1	2.4x
1/29/21	MediConnect Global	Bottomline Technologies	\$8.0	100%	\$35.9	3.4x
1/22/21	Medrium	ServiceSource International	\$32.5	100%	\$5.4	6.0x

USA International

[1] As of the close of the Transaction


Size of Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Transacti on Date	i Target	Acquirer	Transaction Size	% Bought	LTM Revenu es¹	EV/ Revenues
9/5/20	AdvancedMD, Inc.	Global Payments Inc.	\$20.6	100%	\$24.5	6.2x
5/6/20	HEALTHCAREfirst Inc.	Brightree LLC	\$1.6	51%	\$3,505	5.1x
12/9/20	Evimeria EMR AB	Apptix ASA	\$130.0	100%	\$25.7	6.3x
9/6/20	Flatiron Health, Inc.	Roche Holding AG	\$820.0	100%	\$523.6	1.0x
9/24/20	G4S Secure Data Solutions	Metrofile Holdings Limited	\$20.6	100%	\$4.0	1.1x
	Median of the Transactions		\$88.7	100%	\$28.0	2.3x

[1] As of the close of the Transaction



Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions) as of March 31, 2025





Definitions of Financial Terms Used in this Quarterly Industry Update:

Enterprise Value (EV): Market Value of Equity + Market Value of Debt - Cash

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Profitability metric sometimes also referred to as operating profit or operating earnings.

Gross Cash Flows: Net Income + Depreciation and Amortization Expense

Latest Twelve Months (LTM): Financial information is as of the latest twelve months through the date of this Quarterly Industry Update.

Market Value of Invested Capital (MVIC): Market Value of Equity + Market Value of Debt

Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE.



COGENT VALUATION is a nationally recognized full service business valuation firm that has provided independent valuation and financial advisory opinions in thousands of situations since 1991. These assignments include the valuation of companies and pass-through entities, their securities, and their intangible assets ranging in size from small, closely-held businesses and start-ups, to corporations with market values over a billion dollars, covering almost every industry and all types of transactions. With the collective backgrounds of our managing directors and professional staff, Cogent Valuation brings substantial large deal experience to bear on our middle market transaction opinions. Cogent Valuation utilizes proprietary research, intensive due diligence, and the experience and insights of its professionals to produce thoughtful, well-documented opinions that have consistently withstood the scrutiny of clients and their advisors, investors, regulators, and courts.

This industry research is provided at no charge. Further research or detailed information not covered in this report can be obtained for a fee. **Contact Steven Kam at 415-392-0888 or <u>kam@cogentvaluation.com</u> for additional information or questions in connection with this research report.**